MA54521A - SUBSTITUTED OXOPYRIDINE DERIVATIVES - Google Patents
SUBSTITUTED OXOPYRIDINE DERIVATIVESInfo
- Publication number
- MA54521A MA54521A MA054521A MA54521A MA54521A MA 54521 A MA54521 A MA 54521A MA 054521 A MA054521 A MA 054521A MA 54521 A MA54521 A MA 54521A MA 54521 A MA54521 A MA 54521A
- Authority
- MA
- Morocco
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54521A true MA54521A (en) | 2022-03-30 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054521A MA54521A (en) | 2018-12-21 | 2019-12-18 | SUBSTITUTED OXOPYRIDINE DERIVATIVES |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (en) |
| JP (1) | JP2022514303A (en) |
| KR (1) | KR20210106504A (en) |
| CN (1) | CN113474348A (en) |
| AR (1) | AR117435A1 (en) |
| AU (1) | AU2019407909B2 (en) |
| BR (1) | BR112021009435A2 (en) |
| CA (1) | CA3124220A1 (en) |
| CL (1) | CL2021001613A1 (en) |
| CO (1) | CO2021007908A2 (en) |
| CR (1) | CR20210342A (en) |
| DO (1) | DOP2021000128A (en) |
| EA (1) | EA202191764A1 (en) |
| EC (1) | ECSP21043895A (en) |
| IL (1) | IL283990A (en) |
| JO (1) | JOP20210161A1 (en) |
| MA (1) | MA54521A (en) |
| MX (1) | MX2021007508A (en) |
| PE (1) | PE20211790A1 (en) |
| SG (1) | SG11202104384PA (en) |
| TW (1) | TW202039510A (en) |
| WO (1) | WO2020127504A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200232B1 (en) * | 2018-03-15 | 2023-09-17 | Bayer Ag | Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives |
| CN114105881B (en) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | Platelet aggregation inhibitor, and preparation method and application thereof |
| KR20230155505A (en) | 2021-03-09 | 2023-11-10 | 바이엘 악티엔게젤샤프트 | (4S)-24-Chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32H-6-aza-3(4,1 )-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 crystalline form of dibenzenaheptaphane-74-carboxamide |
| KR20230155504A (en) | 2021-03-09 | 2023-11-10 | 바이엘 악티엔게젤샤프트 | (4S)-24-Chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1) Pharmaceutical dosage forms comprising -pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphan-74-carboxamide |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (en) * | 2022-02-25 | 2022-05-31 | 滁州学院 | Preparation method of alkyl alcohol |
| CN116874469B (en) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | Oxo-pyridine compound, intermediate, preparation method and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (en) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituted indazoles |
| JP5419706B2 (en) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | Glucokinase activator |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (en) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | Substituted oxopyridine derivatives |
| CA2918814C (en) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| ES2659045T3 (en) | 2013-10-30 | 2018-03-13 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2694189T3 (en) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| CA2961981A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2712886T3 (en) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa |
| ES2716417T3 (en) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivatives of oxopyridine substituted with anti-inflammatory and antithrombotic action |
| WO2016046166A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2722423T3 (en) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Substituted oxopyridine derivatives |
| EP3271332A1 (en) | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (en) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | Substituted oxopyridine derivatives |
| EP3344618A1 (en) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
-
2019
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/en active Pending
- 2019-12-18 CR CR20210342A patent/CR20210342A/en unknown
- 2019-12-18 MA MA054521A patent/MA54521A/en unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/en unknown
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/en active Pending
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/en active Search and Examination
- 2019-12-18 AR ARP190103745A patent/AR117435A1/en unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/en unknown
- 2019-12-18 TW TW108146372A patent/TW202039510A/en unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/en not_active Application Discontinuation
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/en unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en active Active
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/en unknown
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/en unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/en unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021007908A2 (en) | 2021-07-19 |
| DOP2021000128A (en) | 2021-09-30 |
| MX2021007508A (en) | 2021-08-05 |
| CL2021001613A1 (en) | 2021-12-03 |
| BR112021009435A2 (en) | 2021-08-17 |
| EA202191764A1 (en) | 2021-10-22 |
| TW202039510A (en) | 2020-11-01 |
| ECSP21043895A (en) | 2021-07-30 |
| AU2019407909B2 (en) | 2023-05-25 |
| PE20211790A1 (en) | 2021-09-09 |
| EP3898633A1 (en) | 2021-10-27 |
| CR20210342A (en) | 2021-08-09 |
| CN113474348A (en) | 2021-10-01 |
| JP2022514303A (en) | 2022-02-10 |
| JOP20210161A1 (en) | 2023-01-30 |
| AR117435A1 (en) | 2021-08-04 |
| KR20210106504A (en) | 2021-08-30 |
| AU2019407909A1 (en) | 2021-05-27 |
| IL283990A (en) | 2021-07-29 |
| CA3124220A1 (en) | 2020-06-25 |
| WO2020127504A1 (en) | 2020-06-25 |
| SG11202104384PA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54521A (en) | SUBSTITUTED OXOPYRIDINE DERIVATIVES | |
| MA52942A (en) | OGA INHIBITOR COMPOUNDS | |
| DK3687994T3 (en) | GADOLINIUM-BEARING PCTA-BASED CONTRAST AGENTS | |
| DK3810587T3 (en) | Substituted Alkoxypyridinylindolesulfonamides | |
| MA52939A (en) | OGA INHIBITOR COMPOUNDS | |
| MA52948A (en) | COMPOUNDS | |
| DK3794042T3 (en) | ANTI-MUC1-EXATECET-ANTISTO-DRUG CONJUGATE | |
| MA51669A (en) | COMPOUNDS | |
| MA52004A (en) | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | |
| MA49127A (en) | N-SUBSTITUTED INDOLE DERIVATIVES | |
| MA47420A (en) | OGA INHIBITOR COMPOUNDS | |
| MA53003A (en) | COMPOUNDS | |
| ES2972949T3 (en) | Pesticide-active azolamide compounds | |
| DK3768669T3 (en) | Piperazinazaspiro derivatives | |
| DK3823970T3 (en) | FURTHER SUBSTITUTED TRIAZOLOQUINOXALINE DERIVATIVES | |
| DK3823971T3 (en) | SUBSTITUTED TRIAZOLE-QUINOXALINE DERIVATIVES | |
| MA49704A (en) | ISOTOPIC-LABELED BILIARY ACID DERIVATIVES | |
| DK3796975T3 (en) | SULFONYLAMINOBENZAMIDE DERIVATIVES | |
| MA52946A (en) | COMPOUNDS | |
| ES2972551T3 (en) | Alpha-D-galactopyranoside derivatives | |
| MA53648A (en) | O-GLYCOPROTEIN-2-ACETAMIDO-2-DESOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | |
| MA52934A (en) | OGA INHIBITOR COMPOUNDS | |
| MA52936A (en) | OGA INHIBITOR COMPOUNDS | |
| MA52937A (en) | OGA INHIBITOR COMPOUNDS | |
| MA56504A (en) | PYRIDIN-3-YLE DERIVATIVES |